ClinicalTrials.gg
RecruitingNCT06079112Updated Sep 19, 2024

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

A Phase 1/2 interventional study of 9MW2821 and Toripalimab in Advanced Urothelial Carcinoma, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.

02

Conditions studied

  • Advanced Urothelial Carcinoma
03

In context

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign and date the form e approved by independent ethics committe.
  • Male or female subjects aged 18 to 80 years (including 18 and 80 years).
  • status of 0 or 1.
  • or cytologically confirmed local advanced or urothelial cancer
  • Subjects have received at least 1 line advanced standard therapy or were not treated before
  • Subjects must submit tumor tissues for test
  • of ≥ 12 weeks.
  • Subjects must have according to (version 1.1).
  • Adequate organ functions
  • Sexually active fertile subjects, and their partners, must agree to use methods of during the study and at least 6 months after termination of study therapy.
  • Subjects are willing to follow study procedures.

Exclusion criteria

Exclusion Criteria:

  • Anti-tumor treatment such as chemotherapy and radiotherapy within 21 days prior to the first dose of study drug.
  • Major surgery within 28 days prior to first dose of study drug.
  • /PD-L1/PD-L2 inhibitors used in the previous treatment for La/m UC.
  • Previous treatment with ADCs conjugated with MMAE payload.
  • Clinical significantly toxicity Grade ≥ 2 (except alopecia and pigmentation) related to previous treatment.
  • Peripheral neuropathy Grade ≥ 2.
  • Poorly controlled blood sugar.
  • Increased risks of corneal disease assessed by the investigator prior to the first dose of study drug.
  • Documented history of cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug.
  • Active infections, such as uncontrolled ///TB infection, etc.
  • Other serious or uncontrolled diseases, such as serious interstitial pneumonia/asthma, serious thromboembolic events, etc.
  • Poorly controlled central nervous system .
  • Organ transplantation or hematopoietic stem cell transplantation in the past.
  • History of drug abuse or mental illness.
  • Known allergic sensitivity to any of the ingredients of the study drug.
  • Any P-glycoprotein (P-gp) inducers/inhibitors or potent inducers/inhibitors within 14 days prior to the first dose of study drug.
  • History of disease requiring systemic treatment within 2 years before the first dose.
  • Any within 4 weeks before first dose of study drug or during the study.
  • Use of any drug or medical instruments within 28 days prior to the first dose of study drug.
  • History of another within 3 years before the first dose of study drug. Subjects with curable malignancies are allowed.
  • Other conditions unsuitable into the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    9MW2821+Toripalimab

    Drug: 9MW2821 · Drug: Toripalimab

Interventions

  • 1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.

    Also known as: 9MW2821 injection

  • 240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.

    Also known as: Toripalimab injection

06

What researchers measure

Primary outcomes

  1. incidence of AE/SAE

    adverse event(AE) 、serious adverse event(SAE)

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective Response Rate, ORR

    complete response (CR) or partial response (PR)

    Time frame: Up to 24 months

  2. Duration of Response, DOR

    Time from the date of the first CR or PR to the earliest date of disease progression or death

    Time frame: Up to 24 months

  3. Time To Response, TTR

    Time from the date of first infusion to the date of CR or PR

    Time frame: Up to 24 months

  4. Disease Control Rate, DCR

    the percentage of subjects who experience CR, PR or stable disease (SD)

    Time frame: Up to 24 months

  5. Progression-Free Survival, PFS

    Time from the date of first infusion to the earliest date of disease progression or death

    Time frame: Up to 24 months

  6. Overall Survival, OS

    Time from the date of first infusion to the date of death

    Time frame: Up to 24 months

  7. Pharmacokinetics parameter

    drug concentration of 9MW2821

    Time frame: Up to 12 months

  8. Immunogenicity parameter

    Anti-Drug Antibody (ADA) of 9MW2821

    Time frame: Up to 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 12, 2023
StartActual
Sep 27, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06079112
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Sep 27, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Jun Guo, Professor
Contact
guoj307@126.com
010-88196358

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bulumtatug fuvedotin · Toripalimab

Start the discussion